041830.KQ
InBody Co.,Ltd
KOE · Healthcare · Medical - Specialties · KR
KRW 59,600.00
+1.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 263.9B | 233.9B | 204.5B | 170.4B | 160.0B |
| Cost of Revenue | 65.3B | 59.7B | 46.2B | 38.5B | 42.9B |
| Gross Profit | 198.5B | 174.3B | 158.2B | 131.8B | 117.1B |
| Operating Expenses | |||||
| R&D Expense | 8.8B | 11.8B | 12.3B | 9.3B | 8.8B |
| SG&A Expense | 43.0B | 54.9B | 45.1B | 32.6B | 25.7B |
| General & Admin Expense | 7.5B | 9.4B | 8.1B | 6.0B | 4.5B |
| Selling & Marketing Expense | 35.5B | 45.5B | 37.0B | 26.7B | 21.3B |
| Other Expenses | 98.6B | 71.5B | 64.1B | 45.4B | 40.5B |
| Total Operating Expenses | 147.0B | 138.2B | 121.5B | 87.4B | 75.0B |
| Cost and Expenses | 213.8B | 197.2B | 167.7B | 125.9B | 119.3B |
| Operating Income (EBIT) | 49.9B | 36.1B | 36.7B | 44.5B | 40.7B |
| Non-Operating | |||||
| Interest Income | 3.4B | 3.0B | 3.4B | 3.2B | 1.5B |
| Interest Expense | 513.8M | 504.3M | 384.1M | 329.5M | 122.0M |
| Net Interest Income | 2.9B | 2.5B | 3.0B | 2.9B | 1.4B |
| Other Non-Op Income/Expense | 10.7B | 1.9B | 7.1B | 129.9M | 1.8B |
| Non-Operating Income (excl Interest) | (2.6B) | — | (7.5B) | 6.2B | (2.0B) |
| EBT (Pre-Tax Income) | 60.8B | 38.6B | 43.9B | 44.6B | 42.6B |
| Income Tax Expense | 14.3B | 8.6B | 11.1B | 8.0B | 8.7B |
| Bottom Line | |||||
| Net Income | 46.5B | 30.6B | 33.1B | 36.7B | 33.8B |
| Earnings from Cont. Ops | 46.6B | 30.0B | 32.7B | 36.6B | 34.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 46.9B | 30.6B | 33.1B | 36.7B | 33.8B |
| Per Share | |||||
| Basic EPS | ₩3,546 | ₩2,423 | ₩2,546 | ₩2,819 | ₩2,596 |
| Diluted EPS | ₩3,546 | ₩2,423 | ₩2,546 | ₩2,819 | ₩2,596 |
| Revenue Per Share | ₩19,077 | ₩17,727 | ₩15,778 | ₩13,077 | ₩12,282 |
| Shares | |||||
| Basic Shares Outstanding | 13.8M | 13.2M | 13.0M | 13.0M | 13.0M |
| Diluted Shares Outstanding | 13.8M | 13.2M | 13.0M | 13.0M | 13.0M |
| Profitability Metrics | |||||
| EBITDA | 61.3B | 44.7B | 51.3B | 48.8B | 48.0B |
| D&A | 9.2B | 8.6B | 7.1B | 6.0B | 5.4B |
| EBIT | 52.1B | 36.1B | 44.2B | 42.9B | 42.8B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026